boehringer ingelheim

Boehringer Ingelheim And Enleofen Bio Strike Billion-Dollar Deal

Enleofen Bio will receive more than US$1 billion in earnout payments from Boehringer Ingelheim’s acquisition of worldwide exclusive rights to its preclinical interleukin-11 platform.

Boehringer Ingelheim Opens R&D Lab In China

Boehringer Ingelheim has opened a chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai.

Linagliptin Controlled Type II Diabetes In Asian Clinical Trials

Two phase III clinical studies show that linagliptin improved blood glucose control in Asian adults with type II diabetes.

Boehringer Ingelheim Expands Zhangjiang Plant Into Strategic Supply Center For China

Boehringer Ingelheim announced a US$91 million investment for the expansion of its Zhangjiang High-Tech Park manufacturing plant into a strategically important supply center for China.